Previous Article | Next Article ![]()
Infect Immun, April 1998, p. 1384-1391, Vol. 66, No. 4
Department of Microbiology and Immunology,
Tulane University Medical School, New Orleans, Louisiana
70112-2699,1 and
Department of
Pathology, University of Alabama
Received 3 October 1997/Returned for modification 18 November
1997/Accepted 13 January 1998
Candida albicans mannoprotein (MAN) administered
intravenously to mice stimulates the production of splenic
CD8+ effector cells which downregulate delayed
hypersensitivity (DH) in immunized mice. Cytokine involvement in the
induction and/or elicitation of downregulation was studied by (i)
examining murine splenocytes qualitatively for mRNA for
interleukin-2 (IL-2), IL-4, IL-10, IL-12p40, and gamma interferon
(IFN- We have been investigating
Candida albicans mannoprotein (MAN)-specific
immunomodulation in a murine model of candidiasis. Injection of MAN
intravenously (i.v.) into naive or previously immunized mice stimulates
the development of a CD8+ effector cell which downregulates
MAN-specific delayed hypersensitivity (DH) (24). The
CD8+ cell can be detected directly in immunized mice
treated with MAN, or its presence in splenocyte suspensions can be
demonstrated by transfer from MAN-treated mice into immunized mice just
prior to footpad testing for DH (18, 24). Cells transferred
2 to 4 days following treatment of donor mice with MAN effectively downregulate DH in immunized recipients, whereas cells transferred prior to 48 h do not. Aside from knowing that CD4+ and
I-A+ cells are required for the production of
CD8+ effector cells during the first 30 h following
the injection of MAN (39), little is known of the process by
which the CD8+ cells are induced. It is assumed,
however, that cytokines play a role.
The specific cytokines, and in what sequence they might function, in
the induction of downregulatory effector cells has not been well
defined. However, about 10 years ago, Mosmann et al. (47,
48) described the existence of two subtypes of murine CD4+ cells, Th1 and Th2, which could be distinguished by
the profile of cytokines that they secreted when activated. Numerous
investigators have been analyzing the potential roles of Th1 or Th2
cytokines in various immunologic phenomena since that time. Th1
cytokines, interleukin-2 (IL-2) and gamma interferon (IFN- Only a few investigators have examined the role of cytokines with
respect to downregulation. Notably, Schmitt et al. (61), Ullrich (67), and Rivas and Ullrich (52, 53),
working with a model involving the induction of suppression by UV
radiation, have determined that UV-induced immune suppression resulted
from the secretion of keratinocyte-derived IL-10. IL-4 may also be involved in the immune suppression, as the administration of anti-IL-4 or anti-IL-10 resulted in the abrogation of suppression
(53). The administration of exogenous IL-12 prevented the
induction of immune suppression by UV and also prevented the activity
of preformed suppressor cells (61). In one of the few fungal
models in which cytokine involvement in downregulation has been
studied, increased secretion of IL-5 and decreased secretion of IFN- In this study, we analyzed the pattern and kinetics of cytokine mRNA
expression in unfractionated spleen cells taken from control and
MAN-treated mice. Emphasis was placed on selected cytokines produced by
Th1 and Th2 cells, IL-2/IFN- Experimental animals.
Male CBA/J mice, 6 to 8 weeks of age,
were obtained from Jackson Laboratory, Bar Harbor, Maine. All mice were
housed in bioclean hoods and fed mouse chow and water ad libitum.
Preparation and administration of MAN.
MAN was prepared as
previously described (18) from C. albicans 20A, a
serotype A isolate originally obtained from Errol Reiss, Centers for
Disease Control and Prevention, Atlanta, Ga., using the method of Peat
et al. (51) as modified by Kocourek and Ballou
(37). Briefly, the procedure involves autoclaving C. albicans cells in a citrate buffer to solubilize the mannoprotein, precipitation of the polysaccharide with Fehling's solution,
dissolution of the polysaccharide-copper complexes in HCl to remove the
copper, and then dialyzing the preparation against distilled water to remove any low-molecular-weight components. MAN extracted in this manner contains approximately 5% protein, and mannose is the only sugar detectable (18, 51). The extract was lyophilized and stored in a desiccator prior to use.
0019-9567/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
Cytokine Involvement in Immunomodulatory Activity
Affected by Candida albicans Mannan


Birmingham, Birmingham,
Alabama 35294-00072
![]()
ABSTRACT
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References
), (ii) quantitating splenocyte mRNA for IL-12p40 by
quantitative-competitive reverse transcriptase-mediated PCR, and (iii)
measuring serum levels of IL-12p40 and IL-12p70 by capture
enzyme-linked immunosorbent assay, each performed at selected intervals
over 96 h after giving MAN. Further, the effect of in vivo
administration of anti-IL-4 on the induction and elicitation of
MAN-specific DH in MAN-treated mice was measured. Expression of
IL-12p40 mRNA in the spleen was reduced to near 0 during the first
24 h but rebounded thereafter. Transcripts for IL-10 were
present throughout the 96-h period, whereas those for IL-4 and IFN-
were either weak or undetectable prior to 24 to 48 h. In vivo
administration of anti-IL-4 partially abrogated the downregulatory
effect of MAN only when given at the time of MAN administration. Serum
levels of IL-12p40, but not IL-12p70, were increased by 24 h and
maximal at 48 h. The antagonistic effect of IL-12p40 could
contribute to the mechanism(s) for downregulation of DH. Moreover,
IL-10, IL-4, and/or IFN-
, interacting with MAN-activated cells in
the absence of biologically active IL-12, may induce the production of
CD8+ downregulatory effector cells. Partial abrogation of
downregulatory activity in animals treated with anti-IL-4 at the time
of induction of such activity lends support to this hypothesis.
![]()
INTRODUCTION
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References
), for
example, appear to have prominent roles in cellular immunity, whereas
the Th2 cytokines IL-4, IL-6, and IL-10 drive antibody production. Another cytokine, produced predominantly by antigen-presenting cells,
IL-12, is believed to be the initiator of cellular immunity (62) and a key modulator of the immune system in general
(65, 70). It has been suggested that IL-12 stimulates Th1
cells (62) and simultaneously blocks the differentiation of
Th2 cells (45).
and IL-2 were detected (7).
and IL-4/IL-10, respectively, as well
as on IL-12. In addition, we measured IL-12p40 and IL-12p70 production
by enzyme-linked immunosorbent assay (ELISA). Further, the effect of
anti-IL-4 administered to immunized and/or downregulated mice was
determined. It was clear that IL-4 participated in the induction of
downregulation, but there appeared to be other factors involved as
well, as only partial abrogation of downregulatory activity was
observed. Moreover, increased serum levels of IL-12p40, a potential
antagonist of IL-12p70 (29, 33, 44), may well have permitted
the establishment of the CD8+ effector cells.
![]()
MATERIALS AND METHODS
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References
Preparation of splenic homogenates and isolation of
poly(A)+ RNA.
Total RNA was first isolated by
homogenizing spleens in 2 ml of guanidinium buffer (4 M guanidinium
isothiocyanate, 0.5% sarcosine, 25 mM sodium citrate, 0.7%
-mercaptoethanol). This isolation procedure is based on the
guanidinium thiocyanate-phenol-chloroform extraction method described
by Chomczynski and Sacchi (12). We modified it to include a
second extraction. After centrifugation at 13,000 × g
for 15 min, the RNA in the aqueous phase was precipitated by
isopropanol. RNA precipitates were dissolved in 1 ml of TE buffer (10 mM Tris, 150 mM NaCl, 1 mM EDTA [pH 7.5]) and extracted a second
time. The precipitates were then washed once in 75% ethanol and
resuspended in 200 µl of 0.2% diethyl pyrocarbonate in water. Poly(A)+ RNA was isolated by first heating a mixture
containing 250 µg of RNA in 450 µl of a solution containing 360 µl of 0.1% diethyl pyrocarbonate water, 75 µl of binding buffer
(60 mM Tris-HCl, 6 mM EDTA, 3 M NaCl [pH 7.5]), and 15 µl of
polystyrene latex Oligotex-dT beads (Qiagen, Chatsworth, Calif.) to
65°C for 5 min. Thereafter, the suspension was incubated at room
temperature for 30 min, and the Oligotex-dT beads were washed in TE
buffer. Poly(A)+ RNA was eluted at 80°C from the
polystyrene latex-oligo(dT) beads with elution buffer (5 mM Tris [pH
7.5]). Poly(A)+ RNA was quantitated for each sample by
using multiple dilutions applied to DNA Dipsticks (Invitrogen).
Reverse transcriptase-mediated PCR (RT-PCR) for detection of
cytokine mRNA.
To determine whether a particular cytokine mRNA was
expressed, 300 ng of poly(A)+ RNA, isolated as described
above from murine spleens stimulated with MAN, was reverse transcribed
in the buffer supplied by the manufacturer in the presence of random
hexamer with 200 to 400 U of SuperScript II RNase H
reverse transcriptase or Moloney murine leukemia virus reverse transcriptase (Gibco BRL, Gaithersburg, Md.). The reaction was carried
out at room temperature for 30 min, followed by 90 min at 37°C. The
reverse transcriptase was inactivated at 95°C for 5 min, and the cDNA
was precipitated in ethanol. After the precipitate was washed in 75%
ethanol, 15% of the reverse-transcribed RNA, the equivalent of 40 ng
of input RNA, was used in PCR for the detection of each cytokine gene
in question or for the detection of the housekeeping gene
G3PDH (glyceraldehyde-3-phosphate dehydrogenase). The
amplification reaction included combining the cDNA with 1.25 U of
Taq polymerase, 200 µM deoxynucleoside triphosphates, 1 µg of each primer, 2 to 3 mM MgCl2, and PCR buffer (Gibco
BRL). Positive (concanavalin A-stimulated splenocyte extracts) and
negative (water) controls were included in each assay. Reactions were
assembled with positive-displacement pipettes and brought to 65°C
prior to the addition of Taq polymerase. Each 50-µl sample
was overlaid with 75 µl of mineral oil (Sigma Chemical Co., St.
Louis, Mo.) and placed in a thermal cycler (Robocycler 40 [Stratagene,
La Jolla, Calif.] or Apolitron I [Thermolyne, Dubuque, Iowa]) with temperatures of 95°C for denaturation, 58°C for annealing, and 72°C for extension, with the first 3 of 35 total cycles having extended denaturation and annealing times. Various numbers of cycles
for each cytokine were compared in early experiments, and 35 was in the
linear range for all cytokines tested. Primers were synthesized by the
Midland Certified Reagent Company (Midland, Tex.) according to
sequences selected by one of the authors. The sequences of 5' sense
primers and 3' antisense primers used in this study and their amplified
fragment DNA sizes are summarized in Table
1.
|
Quantitation of IL-12p40 mRNA. Initially the relative quantities of all cytokines were determined visually from photographs of the gels. All poly(A)+ samples from a given experiment representing each of the time intervals tested were subjected to RT-PCR for a specific cytokine mRNA at the same time, using the same percentage of input cDNA; i.e., each reaction was begun transcribing 300 ng of mRNA, and 15% of each transcribed mixture was subjected to PCR and then electrophoresed in the same gel or in two gels placed in the same chamber at the same time. Photographs of the gels were then evaluated independently by three individuals, and the intensity of bands was rated on a scale of 0 to +3. The mean ± standard error of the mean could then be determined by combining the data from all animals. IL-12 was selected for more accurate quantification by quantitative competitive RT-PCR (QC-RT-PCR). Specifically, the amount of IL-12p40 mRNA expressed in a particular sample was determined by the method of Bost and Clements (6) except that the actual quantification was performed by densitometry rather than radiolabeling. Competitor DNA, similar to but demonstrably different in size from IL-12p40 cDNA, but which could be amplified by the same pair of primers, was produced by RT-PCR amplification of plasmid DNA.
For QC-RT-PCR, various dilutions of the IL-12p40 competitor DNA (34 to 25,000 fg) were added to individual tubes, each containing the same amount of cDNA from a particular sample. PCR was carried out as described above with the IL-12p40 primer pair that amplified a 266-bp IL-12p40 fragment. The IL-12p40 competitor, with its 78-bp deletion, amplified a 188-bp IL-12p40 fragment. After PCR, 30% of each reaction mixture was electrophoresed on 2% agarose ethidium bromide-stained gels, the amplified fragments were captured on film, and quantitation was accomplished with an Ultra Scan XL densitometer (Pharmacia LKB, Piscataway, N.J.).Quantitation of secreted IL-12p40 and IL-12p70. Secretion of IL-12p40 into sera was quantified by a capture ELISA as described previously (35). The monoclonal antibody C15.6, which recognizes monomeric or dimeric IL-12p40, was used to coat microtiter plates, and the IL-12p40 captured by this monoclonal antibody was detected by using the biotinylated monoclonal antibody with specificity for a different determinant of IL-12p40, C17.8. A hybridoma secreting the monoclonal antibody C15.6 was kindly provided by G. Trinchieri (Wistar Institute, Philadelphia, Pa.), and the biotinylated antibody produced by C17.8 was purchased from PharMingen (San Diego, Calif.). The sensitivity of this assay was determined to be approximately 10 pg of IL-12p40 per ml.
For detection of IL-12p70, a mixture of two monoclonal antibodies which recognize IL-12p35 (Red-T and G297-289; PharMingen) was used to coat microtiter plates. Following incubation with sera and washing to remove any unbound IL-12, biotinylated anti-IL-12p40 monoclonal antibody C17.8 (PharMingen) was added to detect bound molecules containing both p35 and p40 subunits. ELISA reagents used to detect IL-12p70 could not recognize monomeric or dimeric IL-12p40. The sensitivity of this ELISA was approximately 30 pg of IL-12p70 per ml. Standard curves were developed by using recombinant IL-12p40 and recombinant IL-12p70 (PharMingen) in the above-described assays, and the quantities of each in the test sera were determined by comparison with the standard curves. No attempts were made to distinguish between the quantities of monomeric and dimeric IL-12p40.Preparation of monoclonal anti-IL-4. Anti-IL-4 antibody was harvested from ascites following intraperitoneal (i.p.) injection of 5 × 106 cultured 11B11 hybridoma cells (American Type Culture Collection, Rockville, Md.) into nude mice 10 days after i.p. injection of 0.5 ml pristane (Sigma). The induced ascites were collected beginning at day 10, and purified immunoglobulins were extracted by using a protein A affinity column (Bio-Rad Chemical Division, Richmond, Calif.). The procedures outlined by the manufacturer of the column were followed. Protein was estimated in the purified immunoglobulin preparations by absorbance readings at 280 nm, and mice were treated with the antibodies, based on micrograms of protein per milliliter. Each mouse received 200 to 400 µg of protein/dose i.p. These doses were selected empirically, using as a guideline doses used successfully by others (42, 54, 59).
To determine whether the anti-IL-4 prepared as described above could neutralize IL-4 secreted by the murine cells, IL-4-specific enzyme-linked immunospot (ELISPOT) assays were performed as previously described in detail (40) except that various amounts of anti-IL-4 were incorporated in the medium at a time when the cells would be expected to be secreting cytokine in vitro. Anti-IL-4 was tested at concentrations of 0 to 100 µg of protein/well and rat immunoglobulin at a concentration of 10 µg protein/well.Immunization of mice and measurement of MAN-specific DH. Mice were immunized by the cutaneous inoculation of 106 viable C. albicans on two occasions 2 weeks apart as described previously (28). Animals immunized in this manner develop maximum levels of DH 1 week following the second candidal challenge (19). DH was measured as previously described following the injection of 20 µl of NPS containing 30 µg of MAN into the footpads of mice (18). The footpads were premeasured with calipers and then measured again at 15 min and at 4 and 24 h after the injection of antigen. Since DH in the mouse peaks 24 h after the injection of antigen (reviewed in reference 14), data are reported for that time point.
Statistics. Group sizes for in vivo studies of DH ranged from 6 to 8. The data were analyzed by using the nonparametric Mann-Whitney test.
| |
RESULTS |
|---|
|
|
|---|
Cytokine mRNA expressed by splenocytes in mice stimulated with MAN. We had shown previously that the injection of MAN i.v. into mice stimulated the production of splenic CD8+ effector cells, which downregulated DH when transferred to immunized mice (24). Functional CD8+ cells were not present in transfer suspensions until 2 to 4 days after the injection of MAN (24), and CD4+ and I-A+ cells were required during the first 30 h after the injection of MAN for the induction of the CD8+ cells (39). Therefore, to obtain evidence of cytokine involvement during the induction of this regulatory phenomenon, splenocytes were tested for cytokine mRNA at selected intervals beginning at 2 h and continuing through 96 h after the introduction of MAN. As the experiments summarized below and in Fig. 1 were viewed as surveys designed to identify major changes in cytokine synthesis over time, and since a densitometer was not available to us at the time these analyses were done, it was felt that crude visual examinations would provide the data required for more in-depth studies to follow.
A composite photograph showing gels obtained following RT-PCR for each of the cytokines and for the housekeeping gene G3PDH from a single experiment is presented in Fig. 1. Each lane represents the product from a single mouse, and the products from two mice per observation period are shown. The same mRNA preparation was used for the entire panel of cytokine assays. In addition, the positive and negative controls carried through the RT-PCR procedure at the same time as the experimental samples are shown at the far right. The negative control for IFN-
was mistakenly placed to
the far right of the molecular weight standards when that specific gel
was run. This same type of analysis was performed in two additional experiments. An analysis of the three experiments led us to conclude the following.
|
and IL-4
mRNAs were weak initially, there was considerable message present from
48 to 96 h. Data presented elsewhere wherein ELISPOT assays were
performed are consistent with these observations (40). IL-10
message was strong at all intervals tested. Although in the experiment
shown in Fig. 1, IL-10 mRNA was very weak at 12 h, that was the
only experiment in which that observation was made. Moreover, in the
experiment illustrated in Fig. 1, G3PDH appeared to be
downregulated beginning at about 48 h. Although the transcripts
for G3PDH did, indeed, appear to be less during that
interval in several experiments, that observation was not made for
every experiment and we did not explore it further to confirm or refute
it. If MAN does stimulate a modulation in the synthesis of
G3PDH, however, it would not be the first time that G3PDH mRNA synthesis was modified in response to the
experimental conditions (58).
Of particular interest to us, however, were the observations with
IL-12. There was a constitutive level of IL-12p40 mRNA expressed in
control mice which was reduced to minimal or undetectable levels by
12 h but then returned to control values by 48 h. Since IL-12 is considered a major factor for the initiation of DH (62,
65), and since secreted IL-12p40 is a known antagonist of
bioactive IL-12p70 (29, 33, 44), we decided to pursue a more
stringent quantitative evaluation of IL-12p40 at both the mRNA and
secretory levels, as well as of IL-12p70 at the secretory level.
Message for IL-12p40 was quantitated by QC-RT-PCR. Those data are shown
in Fig. 2. Clearly, IL-12p40 levels were
quite low during the 2- to 24-h interval and were significantly
increased at 96 h. The observations are consistent with the data
shown in Fig. 1. Perhaps the most interesting data, however, were those which resulted from the ELISAs designed to detect IL-12p40 and IL-12p70
in sera taken from mice at selected intervals following the i.v.
administration of MAN (Table 2). There
was no detectable IL-12p70 at any time point between 0 and 96 h
following the administration of MAN. To the contrary, IL-12p40 was
detected, beginning with small quantities at 12 h, which rose
22-fold by 48 h and then dropped to near 12-h levels by 96 h.
|
|
Partial abrogation of downregulatory activity in vivo by administration of anti-IL-4 to immunized and MAN-treated mice. IL-4 was selected for additional study for the following reasons: (i) it was the cytokine for which the greatest increase in the number of spot-forming cells (SFC) was noted in MAN-treated mice during the induction of CD8+ effector cells (40), and (ii) IL-4 has been described as a cytokine required for the induction and elicitation of contact sensitivity (CS) (2, 60, 69). Therefore, if IL-4 is a critical cytokine for the expression of DH to MAN, it would be unlikely to play a role in downregulation, as suggested by the ELISPOT data.
Prior to performing in vivo experiments, however, it was necessary to verify that the anti-IL-4 preparation was capable of neutralizing IL-4. Therefore, two mice each were injected either with saline or MAN, their splenocytes were harvested 96 h later, and ELISPOT assays were initiated. Cells were diluted into 96-well plates and treated with the putative anti-IL-4 during culture. After incubation, IL-4-secreting SFC were detected and the percent decrease after treatment with anti-IL-4 was calculated. The data are summarized in Table 3. Clearly, anti-IL-4 added to the cell cultures neutralized IL-4 secreted by the cells; thus, greatly reduced numbers of SFC were detected in cultures incubated with anti-IL-4. Moreover, the reduction in the number of cells detected was concentration-dependent. When rat immunoglobulin G was used as a control in the system, there appeared to be some nonspecific blocking of the IL-4. However, anti-IL-4 blocked to a much greater extent.
|
|
|
| |
DISCUSSION |
|---|
|
|
|---|
The most interesting observations made here over the 96-h
observation period following the administration of MAN include (i) a
reduction in mRNA synthesis for IL-12p40 within the first 2 h and
continuing through 24 h, (ii) secretion of IL-12p40, beginning with levels barely detectable at 12 h, peaking at 48 h, and
returning to barely detectable at 96 h, (iii) complete lack of
secretion of IL-12p70 at any time after the administration of MAN, (iv) little or no apparent synthesis of mRNA specific for IFN-
and IL-4
for the first 48 h but obvious production thereafter, and (v)
synthesis of IL-10 mRNA throughout the entire period. In addition, partial abrogation of downregulatory activity was affected by the
administration of anti-IL-4 to immunized animals during the induction
phase of the downregulatory activity.
IL-12 is a 70-kDa heterodimeric cytokine composed of covalently linked
35-kDa (p35) and 40-kDa (p40) subunits whose activity was first
described by Kobayashi et al. (36). It is produced predominantly by macrophages and B cells (10, 15), and it is
generally believed to link the innate and acquired immune systems (reviewed in reference 65). IL-12 induces the
production of several cytokines, including IFN-
and IL-2 (66,
70), from T lymphocytes and natural killer (NK) cells in vitro as
well as in vivo (26). Moreover, IL-12 induces the
differentiation of Th1 cells from naive T cells (Th0) (34),
thus initiating cell-mediated immunity. It regulates the proliferation
of not only Th1 cells (34) but also cytotoxic T lymphocytes
(66). This cytokine, therefore, represents an important
regulatory bridge between innate resistance and adoptive immunity
(65).
Since only IL-12p40, and not IL-12p70, the former of which is a known antagonist of IL-12 bioactivity (29, 33, 44), was secreted following the introduction of MAN into naive animals, there was never the opportunity for DH to be initiated. However, the phenomenon observed here is not simply a lack of initiation of DH, in that MAN-specific downregulatory cells that can function to inhibit an established DH response are also produced (24). Thus, it is likely that other cytokines, for example, IL-4 and/or IL-10, play a role during the inductive phase. While we have no evidence at this time with regard to IL-10, we have shown that IL-4-secreting cells were increased in elevated numbers beginning at about 24 h following the introduction of MAN (40) and that the administration of anti-IL-4 to immunized MAN-treated mice partially abrogated the downregulatory activity. Moreover, even if some bioactive IL-12 was produced but remained undetected in the MAN-treated animals, it has been reported in other systems that IL-4 takes precedence over IL-12 when the two cytokines are present at the same time (34, 64, 66).
IL-10 is as interesting as IL-12 with regard to regulation of
cell-mediated immunity, however. IL-10 was originally described as a
factor which prevented the proliferation of Th1 cell clones by
inhibiting IFN-
and IL-2 production (21, 22).
Subsequently, Fiorentino et al. (23) demonstrated that IL-10
acted on antigen-presenting cells to inhibit cytokine synthesis. IL-10,
in fact, has been shown to have many different functions (reviewed in
reference 46), some of which are stimulatory
(11, 41) and some of which are inhibitory (17, 20, 38,
67, 71). The precise role of IL-10 in this MAN-specific system is
unknown at this time, since we have not yet had an opportunity to
investigate the secretion of IL-10 after MAN administration or the
effects of ablation of IL-10 activity in vivo.
The data presented here, as well as those in another study from our
laboratory (40), are not consistent with the hypothesis that
IL-4 is a critical cytokine in the initiation and elicitation of DH to
MAN, such as has been proposed for CS to chemicals. CS is considered
one manifestation of cellular immunity, specifically DH, and two groups
of investigators have proposed that IL-4 is critical for both its
induction (60) and elicitation (69). There are
conflicting data (27), however. Weigmann et al.
(69) speculated that these seemingly contradictory
activities of IL-4 could be explained on the basis of concentration of
IL-4; higher concentrations were inhibitory and lower concentrations
were enhancing. The data obtained, therefore, would depend on the
efficiency with which IL-4 was removed or inhibited in vivo. We have
collected no additional data at this time that would allow us to state
unequivocally how IL-4 and other factors contribute to the induction of
MAN-specific downregulation in murine candidiasis. Reports of
inhibition of cell-mediated immunity and reactive nitrogen oxide
induced by IL-4, IL-10, and transforming growth factor
in parasitic
infections (63), along with data showing the inhibition of
both candidacidal activity and nitric oxide production in
IFN-
-activated macrophages by IL-4 and/or IL-10 (9), may
provide clues for future investigations of the mechanism of action of
cytokines in MAN-induced suppression.
Several laboratories have been investigating additional relationships
between various cytokines and C. albicans
(55-57) or C. albicans MAN (3). IL-12
production has been shown to correlate with the induction of Th1 type
responses in murine candidiasis, and the neutralization of IL-12 by
administration of anti-IL-12 antibody abrogates resistance to C. albicans (55-57). Using human cells in vitro, Ausiello
et al. (3) determined that mannoprotein did not consistently
stimulate the expression of IL-1, IL-5, and IL-10 but did induce
long-lasting production of mRNAs for IL-1
, tumor necrosis factor
alpha, and IL-6, along with appreciable levels of
granulocyte-macrophage colony-stimulating factor, IFN-
, and IL-2.
The stimulation of human cells in vitro appears to be quite different
from the stimulation of murine cells in vivo, particularly with respect
to the stimulation of IFN-
and IL-2, as evidenced from both the mRNA
studies here and the ELISPOT data presented elsewhere (40).
The inability or reduced ability to respond to a normally immunogenic
preparation of an antigen has been a highly controversial area over the
past decade, and the validity of the terms suppression and suppressor
cell have been debated with considerable fervor (30).
Despite the debate, there is no question that the phenomenon occurs; it
has been demonstrated in fungal models by us (8, 18) and
others (5, 13, 16, 32, 49), in bacterial and parasitic
systems (reviewed in reference 68), and in systems involving CS (reviewed in reference 1). There has
been something of a renewed interest in suppressive phenomena; IL-10
production by autoreactive CD8+ T-cell clones has been
described (31), and IL-10 epitopes (43) have been
associated with antigen-specific T suppressor cells. Moreover, Nanda et
al. (50) have described a unique pattern of lymphokine
synthesis involving the cosynthesis of IL-10 and IFN-
in selected
antigen-specific suppressor T-cell clones. IFN-
message was not
upregulated during the induction phase of suppression in the
MAN-specific model, i.e.,
48 h after the injection of MAN, but it was
thereafter. Finally, Buchanan and Murphy (7) reported
increased production of IL-5 in suppressed mice, with decreased
production of IFN-
and IL-2. IL-4 was unchanged.
The role of these downregulatory cells in protective immunity in experimental candidiasis has been incompletely explored. It has been shown that when downregulatory cells are induced in immunized animals, they have no effect on protective immunity when animals are challenged i.v. (25). Since there appears to be a dichotomy of protective mechanisms against C. albicans, however, with cellular immunity being critical against mucosal disease (4), downregulatory cells may well modulate protective immunity at that level. Investigations of immunoregulatory cell involvement in protection at the mucosal level await the development of a suitable animal model in which to demonstrate it.
In summary, our data are suggestive of a role for IL-4, acting in the absence of bioactive IL-12 and presence of potentially antagonistic IL-12p40, in the induction and maintenance of MAN-specific T-cell suppression. Perhaps IL-10 contributes to the induction of the CD8+ effector cells as well, but since only message, and not secretion, was measured for that cytokine, there are no data to support that hypothesis. As a next step, however, it would be appropriate to determine whether in vivo treatment with IL-12 or with anti-IL-10 prevents the induction of the MAN-specific immunomodulatory cells. The most definite experiments will likely involve knockout mice.
| |
ACKNOWLEDGMENTS |
|---|
This investigation was supported by Public Health Service grants AI-12806 (J.E.D.), AI-12913 (S.A.M.), and AI-32976 (K.L.B.) from the National Institute of Allergy and Infectious Diseases.
| |
FOOTNOTES |
|---|
* Corresponding author. Present address: Cratis D. Williams Graduate School, Appalachian State University, Boone, NC 28608. Phone: (828) 262-2130. Fax: (828) 262-2709. E-mail: domerje{at}appstate.edu.
Present address: Alton Ochsner Medical Foundation, New Orleans, LA
70121.
Present address: Sidney Kimmel Cancer Center, San Diego, CA
92121.
Editor: T. R. Kozel
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Asherson, G. L., M. Colizzi, and M. Zembala. 1986. An overview of T-suppressor cell circuits. Annu. Rev. Immunol. 4:37-68[Medline]. |
| 2. | Asherson, G. L., F. Dieli, G. Sireci, and A. Salerno. 1996. Role of IL-4 in delayed type hypersensitivity. Clin. Exp. Immunol. 103:1-4[Medline]. |
| 3. |
Ausiello, C.,
F. Urbani,
S. Gessani,
G. C. Spagnoli,
M. J. Gomez, and A. Cassone.
1993.
Cytokine gene expression in human peripheral blood mononuclear cells stimulated by mannoprotein constituents from Candida albicans.
Infect. Immun.
61:4105-4111 |
| 4. |
Balish, E.,
H. Filutowicz, and R. D. Oberley.
1990.
Correlates of cell-mediated immunity in Candida albicans-colonized gnotobiotic mice.
Infect. Immun.
58:107-113 |
| 5. |
Blackstock, R. J.,
M. McCormack, and N. K. Hall.
1987.
Induction of macrophage-suppressive lymphokine by soluble crytococcal antigens and its association with models of immunologic tolerance.
Infect. Immun.
55:233-239 |
| 6. | Bost, K. L., and J. D. Clements. 1995. In vivo induction of interleukin-12 mRNA expression after oral immunization with Salmonella dublin or the B subunit of Escherichia coli heat-labile enterotoxin. Infect. Immun. 63:1076-1083[Abstract]. |
| 7. |
Buchanan, R. L., and J. W. Murphy.
1994.
Regulation of cytokine production during the expression phase of the anticryptococcal delayed-type hypersensitivity response.
Infect. Immun.
62:2930-2939 |
| 8. | Carrow, E. W., and J. E. Domer. 1985. Immunoregulation in experimental murine candidiasis: specific suppression induced by Candida albicans cell wall glycoprotein. Infect. Immun. 49:171-181. |
| 9. | Cenci, E., L. Romani, A. Mencacci, R. Spaccapelo, E. Schiaffella, P. Puccetti, and F. Bistoni. 1993. Interleukin-4 and interleukin-10 inhibit nitric oxide-dependent macrophage killing of Candida albicans. Eur. J. Immunol. 23:1034-1038[Medline]. |
| 10. |
Chan, S. H.,
B. Perussia,
J. W. Gupta,
M. Kobayashi,
M. Pospisil,
H. A. Young,
S. F. Wolf,
D. Young,
S. C. Clark, and G. Trinchieri.
1991.
Induction of interferon production by natural killer cell stimulatory factor: characterization of the responder cells and synergy with other inducers.
J. Exp. Med.
173:869-879 |
| 11. | Chen, W. F., and A. Zlotnik. 1991. IL-10: a novel cytotoxic T cell differentiation factor. J. Immunol. 147:528-534[Abstract]. |
| 12. | Chomczynski, P., and N. Sacchi. 1987. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 162:156-159[Medline]. |
| 13. |
Cox, R. A., and W. Kennell.
1988.
Suppression of T-lymphocyte response by Coccidioides immitis antigen.
Infect. Immun.
56:1424-1429 |
| 14. | Crowle, A. J. 1975. Delayed hypersensitivity in the mouse. Adv. Immunol. 20:197-264[Medline]. |
| 15. |
D'Andrea, A.,
M. Rengaraju,
N. M. Valiante,
J. Chehimi,
M. Kubin,
M. Aste,
S. H. Chan,
M. Kobayashi,
D. Young,
E. Nickbarg,
R. Chizzonite,
S. F. Wolf, and G. Trinchieri.
1992.
Production of natural killer cell stimulatory factor (interleukin-12) by peripheral blood mononuclear cells.
J. Exp. Med.
176:1387-1398 |
| 16. | Deepe, G. S., Jr., S. R. Watson, and W. E. Bullock. 1984. Cellular origins and target cells of immunoregulatory factors in mice with disseminated histoplasmosis. J. Immunol. 132:2064-2071[Abstract]. |
| 17. | Del Prete, G., M. De Carli, F. Almerigogna, M. G. Giudizi, R. Biagiotti, and S. Romagnani. 1993. Human IL-10 is produced by both type 1 helper (Th1) and type 2 helper (Th2) T cell clones and inhibits their antigen-specific proliferation and cytokine production. J. Immunol. 150:353-360[Abstract]. |
| 18. |
Domer, J. E.,
R. E. Garner, and R. N. Befidi-Mengue.
1989.
Mannan as an antigen in cell-mediated immunity (CMI) assays and as a modulator of mannan-specific CMI.
Infect. Immun.
57:693-700 |
| 19. |
Domer, J. E., and S. A. Moser.
1978.
Experimental murine candidiasis: cell-mediated immunity after cutaneous challenge.
Infect. Immun.
20:88-98 |
| 20. | Enk, A. H., V. L. Angeloni, M. C. Udey, and S. I. Katz. 1993. Inhibition of Langerhans cell antigen-presenting function by IL-10. A role for IL-10 in induction of tolerance. J. Immunol. 151:2390-2398[Abstract]. |
| 21. |
Fernandez-Botran, R.,
V. M. Sanders,
T. R. Mosmann, and E. S. Vitetta.
1988.
Lymphokine-mediated regulation of the proliferative response of clones of T helper 1 and T helper 2 cells.
J. Exp. Med.
168:543-558 |
| 22. |
Fiorentino, D. F.,
M. W. Bond, and T. R. Mosmann.
1989.
Two types of mouse helper T cell. IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones.
J. Exp. Med.
170:2081-2095 |
| 23. | Fiorentino, D. F., A. Zlotnik, T. R. Mosmann, M. Howard, and A. O'Garra. 1991. IL-10 inhibits cytokine production by activated macrophages. J. Immunol. 147:3815-3822[Abstract]. |
| 24. |
Garner, R. E.,
A. M. Childress,
L. G. Human, and J. E. Domer.
1990.
Characterization of Candida albicans mannan-induced, mannan-specific delayed hypersensitivity suppressor cells.
Infect. Immun.
58:2613-2620 |
| 25. |
Garner, R. E., and J. E. Domer.
1994.
Lack of effect of Candida albicans mannan on development of protective immune responses in experimental murine candidiasis.
Infect. Immun.
62:738-741 |
| 26. |
Gately, M. K.,
R. R. Warrier,
S. Honasoge,
D. M. Carvajal,
D. A. Faherty,
S. E. Connaughton,
T. D. Anderson,
U. Sarmiento,
B. R. Hubbard, and M. Murphy.
1994.
Administration of recombinant IL-12 to normal mice enhances cytolytic lymphocyte activity and induces production of IFN- in vivo.
Int. Immunol.
6:157-167 |
| 27. | Gautam, S. C., N. F. Chikkala, and T. A. Hamilton. 1992. Anti-inflammatory action of IL-4. J. Immunol. 148:1411-1415[Abstract]. |
| 28. |
Giger, D. K.,
J. E. Domer, and J. T. McQuitty.
1978.
Experimental murine candidiasis: pathologic and immune responses to cutaneous inoculation with Candida albicans.
Infect. Immun.
19:499-509 |
| 29. | Gillessen, S., D. Carvajal, P. Ling, F. J. Podlaski, D. L. Stremlo, P. C. Familletti, U. Gubler, D. H. Presby, A. S. Stern, and M. K. Gately. 1995. Mouse interleukin-12 (IL-12) p40 homodimer: a potent IL-12 antagonist. Eur. J. Immunol. 25:200-206[Medline]. |
| 30. | Green, D. R., and D. R. Webb. 1993. Saying the "S" word in public. Immunol. Today 14:523-525[Medline]. |
| 31. |
Hisatsune, T.,
K.-I. Nishijima,
Y. Minai,
M. Kohyama, and S. Kaminogawa.
1994.
Autoreactive CD8+ T cell clones producing immune suppressive lymphokines IL-10 and interferon- .
Cell. Immunol.
154:181-192[Medline].
|
| 32. |
Ibrahim, A. B., and D. Pappagianis.
1973.
Experimental induction of anergy to coccidioidin by antigens of Coccidioides immitis.
Infect. Immun.
7:786-794 |
| 33. |
Kato, K.,
O. Shimozato,
K. Hoshi,
H. Wakimoto,
H. Hamada,
H. Yagita, and K. Okumura.
1996.
Local production of the p40 subunit of interleukin 12 suppresses allogeneic myoblast rejection.
Proc. Natl. Acad. Sci. USA
93:9085-9089 |
| 34. | Kennedy, M. K., K. S. Picha, K. D. Shanebeck, D. M. Anderson, and K. H. Brabstein. 1994. Interleukin-12 regulates the proliferation of Th1, but not Th2 or Th0, clones. Eur. J. Immunol. 24:2271-2278[Medline]. |
| 35. | Kincy-Cain, T., and K. L. Bost. 1997. Substance P-induced IL-12 production by murine macrophages. J. Immunol. 158:2334-2339[Abstract]. |
| 36. |
Kobayashi, M.,
L. Fitz,
M. Ryan,
R. M. Hewick,
S. C. Clark,
S. Chan,
R. Loudon,
F. Sherman,
B. Perussia, and G. Trinchieri.
1989.
Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biological effects on human lymphocytes.
J. Exp. Med.
170:827-846 |
| 37. |
Kocourek, J., and C. E. Ballou.
1969.
Method for fingerprinting yeast cell wall mannans.
J. Bacteriol.
100:1175-1181 |
| 38. | Li, L., J. F. Elliott, and T. R. Mosmann. 1994. IL-10 inhibits cytokine production, vascular leakage, and swelling during T helper 1 cell-induced delayed-type hypersensitivity. J. Immunol. 153:3967-3978[Abstract]. |
| 39. | Li, S. P., S. Lee, Y. Wang, and J. E. Domer. 1996. Candida albicans mannan-specific, delayed hypersensitivity down-regulatory CD8+ cells are genetically restricted effectors and their production requires CD4 and I-A expression. Int. Arch. Allergy Immunol. 109:334-343[Medline]. |
| 40. |
Li, S. P.,
S.-I. Lee, and J. E. Domer.
1998.
Alterations in frequency of interleukin (IL-2)-, gamma interferon-, or IL-4-secreting splenocytes induced by Candida albicans mannan and/or monophosphoryl lipid A.
Infect. Immun.
66:1392-1399 |
| 41. | MacNeil, I. A., T. Suda, K. W. Moore, T. R. Mosmann, and A. Zlotnik. 1990. IL-10, a novel growth cofactor for mature and immature T. cells. J. Immunol. 145:4167-4173[Abstract]. |
| 42. | Magee, D. M., and R. A. Cox. 1995. Roles of gamma interferon and interleukin-4 in genetically determined resistance to Coccidioides immitis. Infect. Immun. 63:3514-3519[Abstract]. |
| 43. | Malley, A., M. Zeleny-Pooley, and G. Murray. 1995. Stabilization and characterization of antigen-specific T suppressor inducer and T suppressor effector molecules. J. Immunol. Methods 178:31-39[Medline]. |
| 44. | Mattner, F., S. Fischer, S. Guckes, S. Jin, H. Kaulen, E. Schmitt, E. Rude, and T. Germann. 1993. The interleukin-12 subunit p40 specifically inhibits effects of the interleukin-12 heterodimer. Eur. J. Immunol. 23:2202-2208[Medline]. |
| 45. | McKnight, A. J., G. J. Zimmer, I. Fogelman, S. F. Wolf, and A. K. Abbas. 1994. Effects of IL-12 on helper T cell-dependent immune responses in vivo. J. Immunol. 152:2172-2179[Abstract]. |
| 46. | Moore, K. W., A. O'Garra, R. W. Malefyt, P. Vieira, and T. R. Mosmann. 1993. Interleukin-10. Annu. Rev. Immunol. 11:165-190[Medline]. |
| 47. | Mosmann, T. R., H. Cherwinski, M. W. Bond, M. A. Giedlin, and R. L. Coffman. 1986. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J. Immunol. 136:2348-2357[Abstract]. |
| 48. | Mosmann, T. R., and R. L. Coffman. 1989. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu. Rev. Immunol. 7:145-173[Medline]. |
| 49. | Murphy, J. W., and J. W. Moorhead. 1982. Regulation of cell-mediated immunity in cryptococcosis I. Induction of specific afferent T suppressor cells by cryptococcal antigen. J. Immunol. 128:276-283[Abstract]. |
| 50. |
Nanda, N. K.,
E. E. Sercarz,
D.-H. Hsu, and M. Kronenberg.
1994.
A unique pattern of lymphokine synthesis is a characteristic of certain antigen-specific suppressor T cell clones.
Int. Immunol.
6:731-737 |
| 51. | Peat, S., W. J. Whelan, and T. E. Edwards. 1961. Polysaccharide of baker's yeast. Part IV. Mannan. J. Chem. Soc. (London) 1:29-34. |
| 52. | Rivas, J. M., and S. E. Ullrich. 1992. Systemic suppression of delayed-type hypersensitivity by supernatants from UV-irradiated keratinocytes: an essential role for keratinocyte-derived IL-10. J. Immunol. 149:3865-3871[Abstract]. |
| 53. |
Rivas, J. M., and S. E. Ullrich.
1994.
The role of IL-4, IL-10, and TNF- in the immune suppression induced by ultraviolet radiation.
J. Leukocyte Biol.
56:769-775[Abstract].
|
| 54. |
Romani, L.,
A. Mencacci,
U. Grohmann,
S. Mocci,
P. Mosci,
P. Puccetti, and F. Bistoni.
1992.
Neutralizing antibody to interleukin 4 induces systemic protection and T helper type 1-associated immunity in murine candidiasis.
J. Exp. Med.
176:19-25 |
| 55. |
Romani, L.,
A. Mencacci,
L. Tonnetti,
R. Spaccapelo,
E. Cenci,
S. Wolf,
P. Puccetti, and F. Bistoni.
1994.
Interleukin-12 but not interferon- production correlates with induction of T helper type-1 phenotype in murine candidiasis.
Eur. J. Immunol.
24:909-915[Medline].
|
| 56. | Romani, L., A. Mencacci, L. Tonnetti, R. Spaccapelo, E. Cenci, P. Puccetti, S. F. Wolf, and F. Bistoni. 1994. IL-12 is both required and prognostic in vivo for T helper type 1 differentiation in murine candidiasis. J. Immunol. 152:5167-5175. |
| 57. |
Romani, L.,
S. Mocci,
C. Bietta,
L. Lanfaloni,
P. Puccetti, and F. Bistoni.
1991.
Th1 and Th2 cytokine secretion patterns in murine candidiasis: association of Th1 responses with acquired resistance.
Infect. Immun.
59:4647-4654 |
| 58. | Sabath, D. E., H. E. Broome, and M. B. Prystowsky. 1990. Glyceraldehyde-3-phosphate dehydrogenase mRNA is a major interleukin 2-induced transcript in a cloned T-helper lymphocyte. Gene 91:185-191[Medline]. |
| 59. |
Sadick, M. D.,
F. P. Heinzel,
B. J. Holaday,
R. T. Pu,
R. S. Dawkins, and R. M. Locksley.
1990.
Cure of murine leishmaniasis with anti-interleukin 4 monoclonal antibody. Evidence for a T cell-dependent, interferon -independent mechanism.
J. Exp. Med.
171:115-127 |
| 60. | Salerno, A., F. Dieli, G. Sireci, A. Bellavia, and G. L. Asherson. 1995. Interleukin-4 is a critical cytokine in contact sensitivity. Immunology 84:404-409[Medline]. |
| 61. | Schmitt, E., L. Owen-Schaub, and S. E. Ullrich. 1995. Effect of IL-12 on immune suppression and suppressor cell induction by ultraviolet radiation. J. Immunol. 154:5114-5120[Abstract]. |
| 62. |
Scott, P.
1993.
IL-12: initiation cytokine for cell-mediated immunity.
Science
260:496-497 |
| 63. | Sher, A., R. T. Gazzinelli, I. P. Oswald, M. Clerici, M. Kullberg, E. J. Pearce, J. A. Berzofsky, T. R. Mosmann, S. L. James, H. C. Morse III, and G. M. Shearer. 1992. Role of T-cell derived cytokines in the downregulation of immune responses in parasitic and retroviral infection. Immunol. Rev. 127:183-204[Medline]. |
| 64. | Szabo, S. J., N. G. Jacobson, A. S. Dighe, U. Gubler, and K. M. Murphy. 1995. Developmental commitment to the Th2 lineage by extinction of IL-12 signaling. Immunity 2:665-675[Medline]. |
| 65. | Trinchieri, G. 1995. Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. Annu. Rev. Immunol. 13:251-276[Medline]. |
| 66. |
Trinchieri, G.
1994.
Interleukin-12: a cytokine produced by antigen-presenting cells with immunoregulatory functions in the generation of T-helper cells type 1 and cytotoxic lymphocytes.
Blood
84:4008-4027 |
| 67. | Ullrich, S. E. 1994. Mechanism involved in the systemic suppression of antigen-presenting cell function by UV radiation: keratinocyte-derived IL-10 modulates antigen-presenting cell function of splenic adherent cells. J. Immunol. 152:3410-3416[Abstract]. |
| 68. | Webb, D. R., E. Kraig, and B. H. Devens. 1994. Suppressor cells and immunity in mechanisms of immune regulation. Chem. Immunol. 58:146-192[Medline]. |
| 69. | Weigmann, B., J. Schwing, H. Huber, R. Ross, H. Mossmann, J. Knop, and A. B. Reske-Kunz. 1997. Diminished contact hypersensitivity response in IL-4 deficient mice at a late phase of the elicitation reaction. Scand. J. Immunol. 45:308-314[Medline]. |
| 70. | Wolf, S. F., D. Sieburth, and J. Sypek. 1994. Interleukin 12: a key modulator of immune function. Stem Cells 12:154-168[Abstract]. |
| 71. | Wu, J., R. Q. Cunha, R. Y. Liew, and W. Y. Weiser. 1993. IL-10 inhibits the synthesis of migration inhibitory factor and migration inhibitory factor-mediated macrophage activation. J. Immunol. 151:4325-4332[Abstract]. |
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»